Unosi

• A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics (Basel). (2025)

  V. Barišić, T. Kovačević, M. Travar, A. Golić Jelić, P. Kovačević, D. Milaković, R. Škrbić, A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics (Basel)., Antibiotics, 2025

• The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study (2025)

  V. Barišić, T. Kovačević, M. Travar, P. Kovačević, The Impact of the COVID-19 Pandemic on Antimicrobial Resistance Trends in a Tertiary Care Teaching Hospital: A Ten-Year Surveillance Study, Antibiotics, 2025

• Early treatment with pyridostigmine alleviates heart failure with preserved ejection fraction (HFpEF) in rats (2026-01)

  Marinković S, Šobot T, Maksimović Ž, Đukanović Đ, Uletilović S, Mandić-Kovačević N, Jovičić S, Matičić M, Gajić Bojić M, Stojmenovski A, Bojanić A, Lončar-Stojiljković D, Škrbić R, Stojiljković M., Early treatment with pyridostigmine alleviates heart failure with preserved ejection fraction (HFpEF) in rats, CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, Vol. 104, No. 1, pp. 1 - 11, Jan, 2026

• EVALUATION OF CHENODEOXYCHOLIC ACID AS A CARDIOPROTECTIVE AGENT IN ISOPRENALINE-INDUCED MYOCARDIAL INJURY (2025-11)

  D. Dukanovic, D. Mihajlovic, Z. Maksimovic, S. Marinkovic, U. Malicevic, S. Uletilovic, N. Mandic-Kovacevic, S. Jovicic, Z. Bajic, T. Sobot, M. Mikov, R. Skrbic, EVALUATION OF CHENODEOXYCHOLIC ACID AS A CARDIOPROTECTIVE AGENT IN ISOPRENALINE-INDUCED MYOCARDIAL INJURY, Nov, 2025

• Dijabetesna neuropatija (2023)

  Z. Vukojević, A. Dominović-Kovačević, Dijabetesna neuropatija, Medicinski fakultet, Univerzitet u Banjoj Luci, 2023

• Klinička elektromioneurografija (2024)

  A. Dominović-Kovačević, Z. Vukojević, Klinička elektromioneurografija, Medicinki fakultet, Univerzitet u Banjoj Luci, 2024

• Characteristics of Neuropathic Pain and its Impact on Quality of Life in Patients With Diabetic Polyneuropathy (2020)

  Z. Vukojević, A. Dominović-Kovačević, S. Perić, I. Božović, S. Grgić, I. Basta, D. Lavrnić, Characteristics of Neuropathic Pain and its Impact on Quality of Life in Patients With Diabetic Polyneuropathy, 2020

• Sensory Paraneoplastic Neuropathy as the First Manifestation of the Small-Cell Lung Carcinoma (2023)

  Z. Vukojević, A. Dominović-Kovačević, S. Grgić, S. Mavija, Sensory Paraneoplastic Neuropathy as the First Manifestation of the Small-Cell Lung Carcinoma, 2023

• Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral (2024)

  Z. Vukojević, A. Dominović-Kovačević, S. Grgić, S. Mavija, Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral, 2024

• Lumbar Polydiscopathy or ALS- Diagnostic Challenge: a Case report . (2024)

  Z. Vukojević, A. Dominović-Kovačević, S. Grgić, S. Mavija, Lumbar Polydiscopathy or ALS- Diagnostic Challenge: a Case report ., 2024

• Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathy (2025)

  Z. Vukojević, A. Dominović-Kovačević, S. Grgić, S. Mavija, Characteristics of Neuropathic Pain in Patients with Diabetic Peripheral Neuropathy, 2025

• ALS multisistemska bolest (2026)

  A. Dominović-Kovačević, ALS multisistemska bolest, 2026

• Uticaj đubrenja na vegetativni razvoj i prinos krompira na području opštine Glamoč (2025-12-05T07:50:57.520Z)

• Vascular comorbidites in patients with multiple sclerosis and their impact on physical disability (2022-05)

  D. Tadić, S. Grgić, A. Dominović-Kovačević, M. Nazalević Bursac, S. Mavija, V. Đajić, Vascular comorbidites in patients with multiple sclerosis and their impact on physical disability, Medicinski glasnik Zenica, Vol. 19(2), pp. 166 - 172, May, 2022

• Association between byochemical risk factors for cerebrovascular diseases and clinical phenotype of multiple sclerosis (2025-01)

  D. Tadić, V. Đajić, A. Dominović-Kovačević, Z. Vukojević, B. Zlojutro, M. Jandrić, O. Ljuboja, D. Vranješ, M. Gnjatić, Association between byochemical risk factors for cerebrovascular diseases and clinical phenotype of multiple sclerosis, Časopis udruženja pulmologa Republike Srpske, Vol. 15(1-2), pp. 170 - 178, Jan, 2025

• 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-labek extension study (ATB200-07) (2024)

  B. Schoser, P. Kishnani, D. Batkovic, B. Byrne, K. Claeys, J. Diaz- Manera, P. Laforet, M. Roberts, A. Toscano, A. Van der Ploeg, J. Castelli, M. Goldman, F. Holdbrook, S. Sitaraman, Y. Wasfi, T. Mozaffar, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Kushlaf, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Nevin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Boentert, M. Tchan, M. Freimer, N. Longo, N. Abreu, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-labek extension study (ATB200-07), JOURNAL OF NEUROLOGY, Vol. 271, pp. 2810 - 2823, 2024

• Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient - reported outcome measures in patients with late-onset Pompe disease (2024-11)

  P. Kishnani, B. Byrne, K. Claeys, J. Diaz- Manera, M. Dimachkie, H. Kushlaf, T. Mozaffar, M. Roberts, B. Schoser, N. Hummel, A. Kopiec, F. Holdbrook, S. Shohet, A. Toscano, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Tchan, M. Freimer, N. Longo, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient - reported outcome measures in patients with late-onset Pompe disease, Journal of patient - reported outcomes, Vol. 13;8(1):132, Nov, 2024

• Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease(PROPEL): an international randomised,double-blind, parallel-group,phase 3 trial (2021-12)

  B. Schoser, M. Roberts, B. Byrne, S. Sitaraman, H. Jiang, P. Laforet, A. Toscano, J. Castelli, J. Diaz- Manera, M. Goldman, A. Van der Ploeg, D. Batkovic, S. Kuchipudi, T. Mozaffar, P. Kishnani, A. Sebok, A. Pestronk, A. Dominović-Kovačević, A. Khan, B. Koritnik, C. Tard, C. Lindberg, C. Quinn, C. Eldridge, C. Bodkin, D. Reyes-Leiva, D. Hughes, E. Stefanescu, E. Salort-Campana, E. Butler, F. Bouhour, G. Kim, G. Konstantinos-Papadimas, G. Parenti, H. Bartosik-Psujek, H. Kushlaf, H. Akihiro, H. Lau, H. Pedro, H. Andersen, H. Amartino, H. Shiraishi, H. Kobayashi, I. Tarnev, J. Vengoechea, J. Avelar, J. Shin, J. Cauci, J. Alonso-Perez, J. Janszky, J. Berthy, C. Kornblum, K. Gutschmidt, K. Claeys, M. Judit-Molnar, M. Wencel, M. Tarnopolsky, M. Dimachkie, M. Tchan, M. Freimer, N. Longo, N. Vidal-Fernandez, O. Musumeci, O. Goker-Alpan, P. Deegan, P. Clemens, R. Roxburgh, R. Henderson, R. Hopkin, S. Sacconi, S. Fecarotta, S. Attarian, S. Wenninger, S. Dearmey, T. Hiwot, T. Burrow, T. Ruck, T. Sawada, V. Laszlo, W. Loscher, Y. Chien, Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease(PROPEL): an international randomised,double-blind, parallel-group,phase 3 trial, THE LANCET NEUROLOGY, Vol. 20(12), pp. 1027 - 1037, Dec, 2021

• Thyroid dysfunction in patients with multiple sclerosis:prevalence and associated risk factors (2025-12)

  D. Tadić, S. Grgić, A. Dominović-Kovačević, Z. Vukojević, G. Malešević, V. Stanković-Soldat, Thyroid dysfunction in patients with multiple sclerosis:prevalence and associated risk factors, Biomedicinska istraživanja - Časopis Medicinskog fakulteta Foča, Vol. 16(2), pp. 1 - 12, Dec, 2025

• Vascular comorbidities in patient with multiple sclerosis and their impact on physical disability (2022-06)

  D. Tadić, S. Grgić, A. Dominović-Kovačević, M. Nazalević Bursac, S. Mavija, V. Đajić, Vascular comorbidities in patient with multiple sclerosis and their impact on physical disability, Časopis udruženja pulmologa Republike Srpske, Vol. 19(2), pp. 166 - 172, Jun, 2022